Document Detail

Propafenone for the treatment of refractory complex ventricular ectopic activity.
MedLine Citation:
PMID:  3945115     Owner:  NLM     Status:  MEDLINE    
The results of therapy with propafenone were evaluated in 45 patients with complex ventricular ectopic activity that had been refractory to a mean of 3.8 antiarrhythmic drugs. The cardiac diagnoses were ischemic heart disease (in 16 patients), cardiomyopathy (in 7), mitral valve prolapse (in 7), mitral valve prolapse (in 7), idiopathic ventricular ectopic beats (in 6), valvular heart disease (in 5), and hypertension (in 4). The frequency of ventricular ectopic beats was established after therapy with antiarrhythmic agents had been discontinued. Patients then received propafenone during a dose-ranging protocol. An effective response was defined as a reduction in total ventricular ectopic beats of 80% or more. During dose ranging, therapy failed in four patients because of side effects, in eight because of a reduction in ventricular ectopic beats of less than 80%, and in three because of an aggravation of the arrhythmia. Thirty patients had a reduction in total ventricular ectopic beats of 80% or more. During a mean follow-up of 12.4 months, therapy failed in 1 patient because of sustained ventricular tachycardia and in 7 because of intolerable side effects; 22 patients continued to receive propafenone. PR and QRS intervals were significantly prolonged (P = 0.001), but the corrected QT interval and the heart rate were unchanged. The mean trough plasma level of propafenone associated with an effective response was 756 ng/ml, and that associated with intolerable side effects was 920 ng/ml. Thus, in patients with refractory complex ventricular ectopic beats, propafenone was effective and well tolerated initially in 67% of patients and during long-term administration in 49%, and toxicity was minor in most patients.
S C Hammill; P B Sorenson; D L Wood; D D Sugrue; M J Osborn; B J Gersh; D R Holmes
Related Documents :
3082175 - Prophylactic tocainide or lidocaine in acute myocardial infarction.
2090675 - Pheochromocytoma associated ventricular tachycardia blocked with atenolol.
1889445 - Acute and long-term efficacy of propafenone in patients with sustained ventricular tach...
18373765 - Implantable cardioverter-defibrillators in patients with left ventricular noncompaction.
9568795 - Distinct patterns of t cell receptor distribution of peripheral blood cd8+ cells during...
12843685 - Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and re...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Mayo Clinic proceedings     Volume:  61     ISSN:  0025-6196     ISO Abbreviation:  Mayo Clin. Proc.     Publication Date:  1986 Feb 
Date Detail:
Created Date:  1986-03-04     Completed Date:  1986-03-04     Revised Date:  2013-12-13    
Medline Journal Info:
Nlm Unique ID:  0405543     Medline TA:  Mayo Clin Proc     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  98-103     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Arrhythmias, Cardiac / drug therapy*
Dose-Response Relationship, Drug
Drug Evaluation
Follow-Up Studies
Heart Ventricles
Hemodynamics / drug effects
Middle Aged
Propiophenones / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Propiophenones; 68IQX3T69U/Propafenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dental implants: tissue-integrated prosthesis utilizing the osseointegration concept.
Next Document:  Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity.